Eyegate intends to sell 869,566 common shares through public offering

Funds used for clinical trials, working capital and corporate purposes

By Devika Patel

Knoxville, Tenn., July 15 – Eyegate Pharmaceuticals, Inc. will sell 869,566 common shares in its public sale with a 45-day greenshoe for 130,434 additional shares, according to a Form S-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced as a $15 million offering on June 8.

Aegis Capital Corp. and Chardan Capital Markets, LLC are the bookrunners.

Proceeds will be used for clinical trials, working capital and other general corporate purposes.

EyeGate is a Waltham, Mass.-based pharmaceutical company that is focused on therapeutics and drug-delivery systems for treating eye diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.